Researchers have identified a type of pro-fibrotic immune cell associated with pulmonary fibrosis (PF) in people who develop persistent breathing problems after recovering from COVID-19. The cells’ abundance correlated with the severity of fibrosis, or tissue scarring, as detected by CT scans. “The underlying cells and molecules that contribute…
Frequent appointments and testing are part of life with idiopathic pulmonary fibrosis (IPF). I’ve been living with IPF for eight years now, but the number of those appointments and tests can still overwhelm me, especially as I’m a young adult trying to prioritize my career. These visits…
When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, there didn’t seem to be as much chaos in the world as there is today. Perhaps the drama seemed more distant, or maybe I was just completely engaged in learning about my disease. Today, every…
Insilico Medicine’s ISM001-055 was generally safe and improved lung function in people with idiopathic pulmonary fibrosis (IPF), according to top-line data from a Phase 2a trial. The trial (NCT05938920) enrolled 71 patients with IPF across 21 sites in China who were randomly assigned to receive one of…
I was recently asked when I stopped working and how I knew it was time. First, let me tell you: It wasn’t an easy decision. My idiopathic pulmonary fibrosis (IPF) diagnosis came on Jan. 31, 2017. At the time I was the senior vice president for a U.S.
I do not typically use my columns as a platform to complain about my idiopathic pulmonary fibrosis (IPF). Usually, I try to inform or inspire others; however, that’s not always possible with this cruel and unforgiving disease. I was diagnosed with IPF in 2016 and have been…
At the end of this week, I will complete another trip around the sun. This seemed like an appropriate time to provide you with updates on several columns I have shared in the past year. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, the…
A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the therapy outperformed a placebo at improving lung function or preventing its decline after a year, recently announced top-line data shows.
When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, the disease was a mystery to me. I’ve shared before that when my wife, Susan, and I left the clinic following my diagnosis, we began to search for information from the parking garage. That thirst for…
A University of Colorado professor has won the 2024 Alton Ochsner Award Relating Smoking and Disease for his work into how genetic and environmental factors, including smoking, contribute to a person’s risk of idiopathic pulmonary fibrosis (IPF) — when the disease is due to unknown causes. The $15,000 prize…
Get regular updates to your inbox.
